Objective:
To explore recent breakthroughs in cell and gene therapy (CGT) and assess the maturity of the field.
Approach:
- Event Coverage: Filmed at ARM’s Meeting on the Med 2026 in Rome, featuring discussions with industry leaders.
Key Findings:
- Gene therapies are continuing to demonstrate their potential across a broader range of diseases.
- Regeneron's approval for inherited deafness marks an important milestone for the sector.
- Clinical value is extending beyond oncology into sensory disorders, rare diseases, and other areas of high unmet need.
- Industry leaders discussed innovative regulatory pathways, new reimbursement models, commercialization challenges, and long-term sustainability.
Interpretation:
The field of cell and gene therapy is evolving, with increasing clarity on clinical value and ongoing challenges.
Limitations:
- The discussion does not provide specific data or metrics on therapy effectiveness.
- Challenges in commercialization and long-term sustainability are acknowledged but not detailed.
Conclusion:
The conversation highlights progress and hurdles in making transformative therapies accessible to more patients.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
